We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PAYX:NASDAQPaychex, Inc. Analysis

Data as of 2026-04-23 - not real-time

$90.71

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Paychex, Inc. (PAYX) is trading at $90.71, just below its 20‑day SMA of 91.17 and well under the 200‑day SMA of 115.63, signaling a bearish technical backdrop. The RSI sits at 46, indicating neutral momentum, while the MACD shows a bullish histogram despite the overall bearish trend and decreasing volume. Volatility is elevated at 28.9% 30‑day and beta is low at 0.42, suggesting price swings are more company‑specific than market‑driven. Fundamentally, revenue grew nearly 20% YoY with strong gross (67%) and operating (44%) margins, yet the balance sheet is strained by a debt‑to‑equity ratio of 125 and a dividend payout ratio of 95% that exceeds free cash flow. Valuation metrics show a P/E of 20 versus an industry average of 37**, and a DCF fair value of $61.48, implying the stock is priced well above intrinsic value. The dividend yield of 4.6% is attractive but likely unsustainable given cash flow constraints. Recent news highlights a 20% revenue boost from Paycor synergies, but analyst sentiment remains neutral with a “hold” consensus. Overall, the combination of bearish technicals, overvaluation, and financial leverage tempers the upside from solid growth and dividend appeal.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price just below short‑term moving average
  • Decreasing volume and bearish trend direction
  • High dividend yield but questionable sustainability

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Robust 20% revenue growth and strong margins
  • Overvaluation relative to DCF fair value
  • Elevated leverage (debt‑to‑equity ~125)

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Stock priced well above intrinsic value
  • High payout ratio with zero free cash flow
  • Significant debt burden limiting financial flexibility

Key Metrics & Analysis

Financial Health

Revenue Growth19.90%
Profit Margin26.63%
P/E Ratio20.0
Debt/Equity124.91
P/B Ratio8.1
Op. Cash Flow$1.2B
Industry P/E36.9

Technical Analysis

TrendBearish
RSI46.5
Support$85.45
Resistance$96.24
MA 20$91.17
MA 50$92.52
MA 200$115.63
MACDBullish
VolumeDecreasing
Fear & Greed Index86.7

Valuation

Fair Value$61.48
Target Price$100.93
Upside/Downside11.27%
GradeOvervalued
TypeValue
Dividend Yield4.62%

Risk Assessment

Beta0.42
Volatility28.88%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.